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Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are 
clinically disparate primary liver cancers (PLC) with etiological and biological 
heterogeneity and are the primary cause of cancer mortality in Thailand.  The Thailand 
Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) 
consortium was established to identify genomic factors related to PLC risk, genetic 
susceptibility, and progression.  We determined molecular subtypes among PLC 
patients by systematic integration of genomic, transcriptomic, and metabolic profiles. 
Genome wide profiling of 398 surgical specimens derived from 199 PLC patients was 
performed by Affymetrix HTA2.0 (transcriptome), Affymetrix Genome-Wide Human SNP 
Array 6.0 (somatic copy number alterations) and Metabolon's DiscoveryHD4 platform 
(metabolome). Unsupervised Consensus Clustering (cCluster), Subclass Mapping (SM), 
Gene Set Enrichment Analysis (GSEA), class comparison, loss of heterozygosity and 
minimum segmentation, Pearson and rank correlation algorithms were used to analyze 
and validate omics data in 852 Asian and Caucasian PLC cases. Thai HCC and ICC 
consisted of several stable molecular subtypes linked to similar prognosis that were 
validated in 247 Chinese HCC, 156 Asian American HCC and 182 Japanese ICC, but 
not in 163 European American HCC or 104 Caucasian ICC patients. While ICC and 
HCC share recurrently mutated genes, including TP53, ARID1A, and ARID2, mitotic 
checkpoint anomalies distinguish the C1 subtype with key drivers PLK1 and ECT2, 
whereas the C2 subtype is linked to obesity, T-cell infiltration and bile acid metabolism.  
Thus, Asian ICC and HCC, while clinically treated as separate entities, share common 
molecular subtypes with similar actionable drivers to improve precision therapy. 
 
